Researchers at Denmark-based Bactolife are designing targeted protein molecules called Binding Proteins to target toxins from harmful pathogens that have infiltrated the gastrointestinal tract while leaving the beneficial gut microbiome alone.
In a bid to advance its platform, the company has just raised €30m ($33m).
Bactolife raised the funds in a Series A round led by ATHOS with participation from the Bill & Melinda Gates Foundation and Novo Holdings. The company previously raised €7m in seed financing in April 2021.